Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02908477 · ClinicalTrials.gov registry record · Phase 3

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

A Phase 3 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 3
Development phase
228
Enrollment target

NCT02908477: Completed Phase 3 study, sponsored by Mayo Clinic.

NCT02908477 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 228 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02908477, a Phase 3 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 3
Development phase
228 participants
Enrollment target

Study Summary

This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses half the dose of radiation given over two weeks rather than six weeks. Patients will be randomly assigned to receive the less intense treatment versus the traditional treatment by coin flip. Patients are twice as likely to receive the less intense treatment during randomization.

Primary Outcome

To compare rate of late grade 3-5 toxicities between de-escalated adjuvant radiation therapy (DART) and standard adjuvant therapy.

Interventions

  • DRUG Docetaxel
  • DRUG Cisplatin
  • RADIATION Adjuvant Radiation Therapy

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2016-10-03
Est. Completion 2024-11-15
Phase Phase 3
Mayo Clinic

2,844 total trials

What the finished NCT02908477 record still lists

NCT02908477 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.

NCT02908477 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02908477 about?

NCT02908477 is a clinical study titled "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer". This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses hal...

What is the current status of trial NCT02908477?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2016-10-03. Estimated completion is 2024-11-15.

What interventions are being tested in trial NCT02908477?

The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Adjuvant Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT02908477?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02908477's enrollment target sits among peer trials

228 1309th of 2000 higher than 691 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05107908 · 228 participants · NA

    Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity

  • NCT05547698 · 228 participants · NA

    A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation

  • NCT05630963 · 228 participants

    Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

  • NCT06073665 · 228 participants · Phase 4

    Dosing of LT4 in Older Individuals

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02908477, the US trial registry maintained by the National Library of Medicine. NCT02908477 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.